Literature DB >> 1381586

Effects of Taxotere on murine and human tumor cell lines.

J F Riou1, A Naudin, F Lavelle.   

Abstract

Taxotere (RP 56976, NSC 628503), an analog of taxol, is an inhibitor of depolymerisation of microtubules and is currently in Phase I clinical trials. Comparisons of the cytotoxicities of Taxotere and taxol have been studied on several murine (P388, SVras) and human cell lines (Calc18, HCT116, T24, N417, KB). Taxotere was found more potent than taxol (1.3-12 fold), a result which could be explained by its higher affinity than taxol for microtubules. In agreement with its postulated mechanism of action, Taxotere is more cytotoxic on proliferating than on non proliferating N417 cells and does not inhibit cellular DNA, RNA and protein synthesis. Taxotere gives partial cross resistance on P-glycoprotein resistant P388/DOX cell line, in contrast to taxol which gives a complete cross resistance. On the other hand, no cross resistances were observed on Calc18/AM and P388/CPT5 cell lines, bearing modified activities of topoisomerase II and topoisomerase I, respectively. These results underline the higher cytotoxic activity of Taxotere compared to taxol, and the lack of cross resistance of that class of agent with the topoisomerase I and II-related multidrug resistance phenotypes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381586     DOI: 10.1016/s0006-291x(05)81474-3

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  22 in total

1.  Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands.

Authors:  J F Riou; L Guittat; P Mailliet; A Laoui; E Renou; O Petitgenet; F Mégnin-Chanet; C Hélène; J L Mergny
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

Review 2.  Docetaxel: an update of its use in advanced breast cancer.

Authors:  D P Figgitt; L R Wiseman
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

3.  Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus.

Authors:  Elisabeth I Heath; Susan Urba; John Marshall; Steven Piantadosi; Arlene A Forastiere
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

Review 4.  New microtubular agents in pediatric oncology.

Authors:  N L Seibel; G H Reaman
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 5.  Emerging drug treatments for solid tumours.

Authors:  J H Schellens; L C Pronk; J Verweij
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

6.  Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study.

Authors:  M Sanson; M Napolitano; R Yaya; F Keime-Guibert; P Broët; K Hoang-Xuan; J Y Delattre
Journal:  J Neurooncol       Date:  2000-12       Impact factor: 4.130

7.  Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines.

Authors:  M Taron; C Plasencia; A Abad; C Martin; M Guillot
Journal:  Invest New Drugs       Date:  2000-05       Impact factor: 3.850

8.  Assay-based response evaluation in head and neck oncology: requirements for better decision making.

Authors:  Andreas Dietz; Andreas Boehm; Iris-Susanne Horn; Pierre Kruber; Ingo Bechmann; Wojciech Golusinski; Dietger Niederwieser; Ralph Dollner; Torsten W Remmerbach; Christian Wittekind; Stephan Dietzsch; Guido Hildebrandt; Gunnar Wichmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-01-06       Impact factor: 2.503

9.  Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro.

Authors:  B T Hill; R D Whelan; S A Shellard; S McClean; L K Hosking
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

10.  Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer.

Authors:  B Burtness; M Gibson; B Egleston; R Mehra; L Thomas; R Sipples; M Quintanilla; J Lacy; S Watkins; J R Murren; A A Forastiere
Journal:  Ann Oncol       Date:  2009-05-08       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.